Sofinnova Partners is a venture capital firm specializing in life sciences and sustainability investments. The company provides capital and strategic support to start-ups, early-stage, and growth-stage companies in the biotech, medtech, and green tech sectors. With a focus on innovation and sustainability, Sofinnova Partners aims to support companies that have the potential to make a significant impact on health and the environment.

Jean Deleage

Sofinnova Partners

Sofinnova Investments is a healthcare investment firm committed to funding innovative products that aspire to meaningfully impact the lives of patients. We invest in both private and public equity companies. Sofinnova actively partners with entrepreneurs across all stages of company formation, we are long-term investors with extensive scientific expertise, vast industry knowledge, and a track record of helping forge the path from drug development and navigating the regulatory process to company building and IPO or M&A. Founded in 1976, Sofinnova has a long legacy of building what we believe are great companies in both the U.S. and Europe with approximately $3.7B in assets under management and committed capital as of 12/31/2023. 

Spark Therapeutics

Vera Therapeutics

Bolt Biotherapeutics

Coherus Biosciences

IVERIC bio

Enovix

Humanigen

Marinus Pharmaceuticals

Natera

Prothena

Aerovate Therapeutics

Akouos

Apellis Pharmaceuticals

Seagen

Seres Therapeutics

Athira Pharma

Gyroscope Therapeutics

immatics biotechnologies

Infovista

Invitae

Sofinnova Investments 

Metric
Company Name	Sofinnova Partners
Symbol
MSH ID	COM:SOFINNOVA
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital
Country	US
Stage
Employee Count	49
Website	sofinnova.com
LinkedIn	sofinnova-ventures
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	5.75K
Web Traffic Growth	-0.08
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:SOFINNOVA

Sofinnova Partners

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue